Evercore ISI Upgrades Compass Pathways to Outperform with Price Target Raised to $21
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 hours ago
0mins
Source: seekingalpha
- Rating Upgrade: Evercore ISI upgraded Compass Pathways from Inline to Outperform and raised its price target from $8 to $21, reflecting increased confidence in the long-term efficacy of its psychedelic therapy COMP360.
- Clinical Trial Results: The 26-week results from the 581-patient Phase 3 COMP006 trial demonstrated rapid onset and durable clinical effects of COMP360, further solidifying its potential in treating treatment-resistant depression.
- FDA Expectations: Analysts anticipate FDA approval for COMP360 in H1 2027, with initial commercial rollout expected to be slow, yet this sets a foundation for long-term growth in the mental health sector.
- Infrastructure Development: As the necessary infrastructure is built, Compass Pathways plans to gradually launch COMP360 over the next few quarters, facing initial challenges but maintaining an optimistic long-term outlook.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CMPS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CMPS
Wall Street analysts forecast CMPS stock price to rise
7 Analyst Rating
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 12.990
Low
8.00
Averages
18.43
High
40.00
Current: 12.990
Low
8.00
Averages
18.43
High
40.00
About CMPS
Compass Pathways plc is a United Kingdom-based biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. The Company is engaged in treating mental health conditions focused on rapid and durable responses through the development of its investigational COMP360 psilocybin treatment. COMP360 is its psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity. The Company’s initial focus is on treatment-resistant depression (TRD), comprising patients who are inadequately served by the current treatment paradigm. It commenced its Phase III program evaluating its COMP360 psilocybin treatment in TRD. In addition, the Company has ongoing Phase II trials in PTSD and anorexia nervosa. It also provides support to research institutions conducting investigator-initiated studies with COMP360 psilocybin in areas of serious unmet need.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Positive COMP360 Data Boosts Stock Price
- Positive Clinical Data: Compass Pathways PLC (CMPS) announced that its second late-stage trial of COMP360 showed significant symptom relief for patients with treatment-resistant depression, with effects lasting at least six months, potentially paving the way for a future FDA application.
- Analyst Ratings Remain Optimistic: Analysts from Stifel, Oppenheimer, and Wolfe Research maintained positive ratings on CMPS, with Oppenheimer setting a price target of $20, indicating a potential upside of about 54%, reflecting a strong belief in the long-term market opportunity for COMP360 despite the current stock price not fully capturing its potential.
- Market Reaction Volatility: CMPS shares experienced a trading session with swings of up to 10%, ultimately closing up 1% at $12.99, indicating that investors were taking profits after the positive data release; analysts suggest this volatility may be an overreaction to good news, with expectations of a rebound in momentum.
- Retail Investor Sentiment Bullish: According to a Stocktwits poll, retail sentiment around CMPS remains in the 'bullish' zone, with 25% of approximately 750 respondents expressing confidence in the stock's prospects over the next five years, further supporting its market outlook.
See More
Compass Pathways Releases New Data on COMP360 for Treatment-Resistant Depression
- Clinical Trial Progress: Compass Pathways confirmed the potential of COMP360 against treatment-resistant depression in its 581-patient Phase 3 COMP006 trial, with 26-week results demonstrating rapid onset and durable clinical effects, boosting market confidence in its therapy.
- Efficacy Data Highlights: In the COMP006 trial, 39% of patients receiving two doses of 25 mg COMP360 achieved at least a 25% reduction in MADRS scores by Week 6, compared to only 25% in the COMP005 trial, indicating the clinical benefits of dose escalation.
- Safety Profile Remains Strong: The experimental therapy showed no new safety events and continued to indicate a well-tolerated safety profile, enhancing investor confidence in its future market performance.
- FDA Application Progress: Compass Pathways is conducting a rolling submission for a new drug application expected to conclude in Q4 2024, with COMP360 anticipated to launch in H1 2027, subject to FDA approval, further driving company growth.
See More
Compass Pathways' COMP360 Shows Strong Phase 3 Data for TRD
- Clinical Trial Results: Among patients receiving a 25 mg dose, 39% achieved a clinically meaningful reduction in depression symptoms by Week 6 and maintained these benefits through at least Week 26, significantly improving on the 25% response rate seen in the COMP005 trial, indicating COMP360's potential in treating treatment-resistant depression (TRD).
- Positive Stock Reaction: Shares of Compass Pathways jumped over 10% in pre-market trading on Tuesday, and if current levels hold after the opening bell, it would mark the biggest single-day gains in nearly two months, reflecting strong market confidence in the new therapy.
- FDA Application Progress: The company has begun a rolling New Drug Application submission to the U.S. FDA, with the final filing expected in Q4 2026, and if approved, COMP360 is anticipated to launch in the first half of 2027, further advancing its late-stage PTSD program.
- Optimistic Market Sentiment: Retail sentiment surrounding CMPS on Stocktwits remained in the 'bullish' zone, with message volumes surging 225% over a 24-hour period, as some users predict the stock could climb to $20 before the closing bell, representing a potential 35% increase.
See More
COMP360 Shows Breakthrough Progress in Treatment-Resistant Depression
- Clinical Trial Results: COMP360 demonstrated that 39% of participants in the COMP006 Phase 3 trial achieved a clinically meaningful reduction in depressive symptoms by week six, with effects maintained for at least 26 weeks, indicating its potential value in treating treatment-resistant depression.
- Safety Profile: COMP360 exhibited a generally well-tolerated and safe profile in a highly chronic depression population, with the majority of treatment-emergent adverse events being transient and occurring predominantly on the day of dosing, underscoring its safety and tolerability.
- NDA Progress: The rolling New Drug Application (NDA) for COMP360 is underway, with final submission expected to be completed in Q4 2026, and a commercial launch anticipated in the first half of 2027, marking a significant milestone for the company in the mental health space.
- Market Potential: The successful development of COMP360 could provide new treatment options for millions of patients with treatment-resistant depression, potentially transforming the standard of mental health care, reducing patient suffering, and improving quality of life.
See More
Compass Pathways Grants Equity Awards to New Employees
- Equity Award Program: Compass Pathways plc granted equity awards on July 1, 2026, to eight newly hired non-executive employees, totaling 63,685 stock options and 30,300 restricted share units, aimed at attracting and retaining key talent, thereby enhancing the company's competitive edge in the mental health sector.
- Option Exercise Price: The granted options have an exercise price of $13.29 per share, matching the closing price of the company's American Depositary Shares on the grant date, which aligns employee interests with company performance and promotes long-term value creation.
- Vesting Schedule: These options will vest over four years, with 25% vesting on the first anniversary and the remaining 75% vesting in equal monthly installments, a structure that not only incentivizes long-term employee retention but also enhances team stability and execution capability.
- Regulatory Compliance: In accordance with NASDAQ Listing Rule 5635(c)(4), the equity awards were approved by the Compensation and Leadership Development Committee of the Board, ensuring the company's compliance and transparency in talent attraction efforts.
See More
Rapid Growth in Major Depressive Disorder Treatment Market
- Market Growth Potential: The global Major Depressive Disorder treatment market is projected to grow from approximately $20 billion in 2026 to nearly $36 billion by 2033, reflecting strong long-term demand and attracting billions in investment.
- Clinical Trial Progress: Helus Pharma's HLP003 has surpassed 88% enrollment in the Phase 3 APPROACH study for MDD, with topline data expected in Q4 2026, marking a significant step towards commercialization.
- Significant Efficacy: Phase 2 data for HLP003 demonstrated a ~23-point reduction in MADRS score at 12 months after two 16mg doses, achieving a 100% response rate and 71% remission rate, indicating its potential in treating treatment-resistant depression.
- Strategic Partnerships: Helus Pharma has partnered with TARA Mind to enhance access to mental health treatment for veterans and collaborates with leading mental health organizations to support HLP003 Phase 3 recruitment, further expanding its market impact.
See More
Positive COMP360 Data Boosts Stock Price
- Positive Clinical Data: Compass Pathways PLC (CMPS) announced that its second late-stage trial of COMP360 showed significant symptom relief for patients with treatment-resistant depression, with effects lasting at least six months, potentially paving the way for a future FDA application.
- Analyst Ratings Remain Optimistic: Analysts from Stifel, Oppenheimer, and Wolfe Research maintained positive ratings on CMPS, with Oppenheimer setting a price target of $20, indicating a potential upside of about 54%, reflecting a strong belief in the long-term market opportunity for COMP360 despite the current stock price not fully capturing its potential.
- Market Reaction Volatility: CMPS shares experienced a trading session with swings of up to 10%, ultimately closing up 1% at $12.99, indicating that investors were taking profits after the positive data release; analysts suggest this volatility may be an overreaction to good news, with expectations of a rebound in momentum.
- Retail Investor Sentiment Bullish: According to a Stocktwits poll, retail sentiment around CMPS remains in the 'bullish' zone, with 25% of approximately 750 respondents expressing confidence in the stock's prospects over the next five years, further supporting its market outlook.
See More
Compass Pathways Releases New Data on COMP360 for Treatment-Resistant Depression
- Clinical Trial Progress: Compass Pathways confirmed the potential of COMP360 against treatment-resistant depression in its 581-patient Phase 3 COMP006 trial, with 26-week results demonstrating rapid onset and durable clinical effects, boosting market confidence in its therapy.
- Efficacy Data Highlights: In the COMP006 trial, 39% of patients receiving two doses of 25 mg COMP360 achieved at least a 25% reduction in MADRS scores by Week 6, compared to only 25% in the COMP005 trial, indicating the clinical benefits of dose escalation.
- Safety Profile Remains Strong: The experimental therapy showed no new safety events and continued to indicate a well-tolerated safety profile, enhancing investor confidence in its future market performance.
- FDA Application Progress: Compass Pathways is conducting a rolling submission for a new drug application expected to conclude in Q4 2024, with COMP360 anticipated to launch in H1 2027, subject to FDA approval, further driving company growth.
See More
Compass Pathways' COMP360 Shows Strong Phase 3 Data for TRD
- Clinical Trial Results: Among patients receiving a 25 mg dose, 39% achieved a clinically meaningful reduction in depression symptoms by Week 6 and maintained these benefits through at least Week 26, significantly improving on the 25% response rate seen in the COMP005 trial, indicating COMP360's potential in treating treatment-resistant depression (TRD).
- Positive Stock Reaction: Shares of Compass Pathways jumped over 10% in pre-market trading on Tuesday, and if current levels hold after the opening bell, it would mark the biggest single-day gains in nearly two months, reflecting strong market confidence in the new therapy.
- FDA Application Progress: The company has begun a rolling New Drug Application submission to the U.S. FDA, with the final filing expected in Q4 2026, and if approved, COMP360 is anticipated to launch in the first half of 2027, further advancing its late-stage PTSD program.
- Optimistic Market Sentiment: Retail sentiment surrounding CMPS on Stocktwits remained in the 'bullish' zone, with message volumes surging 225% over a 24-hour period, as some users predict the stock could climb to $20 before the closing bell, representing a potential 35% increase.
See More
COMP360 Shows Breakthrough Progress in Treatment-Resistant Depression
- Clinical Trial Results: COMP360 demonstrated that 39% of participants in the COMP006 Phase 3 trial achieved a clinically meaningful reduction in depressive symptoms by week six, with effects maintained for at least 26 weeks, indicating its potential value in treating treatment-resistant depression.
- Safety Profile: COMP360 exhibited a generally well-tolerated and safe profile in a highly chronic depression population, with the majority of treatment-emergent adverse events being transient and occurring predominantly on the day of dosing, underscoring its safety and tolerability.
- NDA Progress: The rolling New Drug Application (NDA) for COMP360 is underway, with final submission expected to be completed in Q4 2026, and a commercial launch anticipated in the first half of 2027, marking a significant milestone for the company in the mental health space.
- Market Potential: The successful development of COMP360 could provide new treatment options for millions of patients with treatment-resistant depression, potentially transforming the standard of mental health care, reducing patient suffering, and improving quality of life.
See More
Compass Pathways Grants Equity Awards to New Employees
- Equity Award Program: Compass Pathways plc granted equity awards on July 1, 2026, to eight newly hired non-executive employees, totaling 63,685 stock options and 30,300 restricted share units, aimed at attracting and retaining key talent, thereby enhancing the company's competitive edge in the mental health sector.
- Option Exercise Price: The granted options have an exercise price of $13.29 per share, matching the closing price of the company's American Depositary Shares on the grant date, which aligns employee interests with company performance and promotes long-term value creation.
- Vesting Schedule: These options will vest over four years, with 25% vesting on the first anniversary and the remaining 75% vesting in equal monthly installments, a structure that not only incentivizes long-term employee retention but also enhances team stability and execution capability.
- Regulatory Compliance: In accordance with NASDAQ Listing Rule 5635(c)(4), the equity awards were approved by the Compensation and Leadership Development Committee of the Board, ensuring the company's compliance and transparency in talent attraction efforts.
See More
Rapid Growth in Major Depressive Disorder Treatment Market
- Market Growth Potential: The global Major Depressive Disorder treatment market is projected to grow from approximately $20 billion in 2026 to nearly $36 billion by 2033, reflecting strong long-term demand and attracting billions in investment.
- Clinical Trial Progress: Helus Pharma's HLP003 has surpassed 88% enrollment in the Phase 3 APPROACH study for MDD, with topline data expected in Q4 2026, marking a significant step towards commercialization.
- Significant Efficacy: Phase 2 data for HLP003 demonstrated a ~23-point reduction in MADRS score at 12 months after two 16mg doses, achieving a 100% response rate and 71% remission rate, indicating its potential in treating treatment-resistant depression.
- Strategic Partnerships: Helus Pharma has partnered with TARA Mind to enhance access to mental health treatment for veterans and collaborates with leading mental health organizations to support HLP003 Phase 3 recruitment, further expanding its market impact.
See More
